innate

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
Clément Anfray, Francesco Mainini, Elisabeth Digifico, Akihiro Maeda, Marina Sironi, Marco Erreni, Achille Anselmo, Aldo Ummarino, Sara Gandoy, Francisco Expósito, Miriam Redrado, Diego Serrano, Alfonso Calvo, Marvin Martens, Susana Bravo, Alberto Mantovani, Paola Allavena, Fernando Torres Andón

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e002408; DOI: 10.1136/jitc-2021-002408
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
Shifaa M. Abdin, Daniela Paasch, Michael Morgan, Nico Lachmann

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002741; DOI: 10.1136/jitc-2021-002741
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
Mireia Bachiller, Lorena Perez-Amill, Anthony Matthew Battram, Sebastian Ciro Carné, Amer Najjar, Els Verhoeyen, Manel Juan, Alvaro Urbano-Ispizua, Beatriz Martin-Antonio

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002866; DOI: 10.1136/jitc-2021-002866
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
Casey R Ager, Akash Boda, Kimal Rajapakshe, Spencer Thomas Lea, Maria Emilia Di Francesco, Priyamvada Jayaprakash, Ravaen B Slay, Brittany Morrow, Rishika Prasad, Meghan A Dean, Colm R Duffy, Cristian Coarfa, Philip Jones, Michael A Curran

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003246; DOI: 10.1136/jitc-2021-003246
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
Si-Yu Wu, Yi Xiao, Jin-Li Wei, Xiao-En Xu, Xi Jin, Xin Hu, Da-Qiang Li, Yi-Zhou Jiang, Zhi-Ming Shao

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002528; DOI: 10.1136/jitc-2021-002528
Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
Haibo Sun, Thomas G Martin, John Marra, Denice Kong, Jonathon Keats, Sandrine Macé, Marielle Chiron, Jeffrey L Wolf, Jeffrey M Venstrom, Raja Rajalingam

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002958; DOI: 10.1136/jitc-2021-002958
S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation
Shuangqing Liu, Huilei Zhang, Yanan Li, Yana Zhang, Yangyang Bian, Yanqiong Zeng, Xiaohan Yao, Jiajia Wan, Xu Chen, Jianru Li, Zhaoqing Wang, Zhihai Qin

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002548; DOI: 10.1136/jitc-2021-002548
G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
Paula Martinez Sanz, Dieke J van Rees, Lieke M J van Zogchel, Bart Klein, Panagiota Bouti, Hugo Olsman, Karin Schornagel, Ivana Kok, Ali Sunak, Kira Leeuwenburg, Ilse Timmerman, Miranda P Dierselhuis, Waleed M Kholosy, Jan J Molenaar, Robin van Bruggen, Timo K van den Berg, Taco W Kuijpers, Hanke L Matlung, Godelieve A M Tytgat, Katka Franke

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e002259; DOI: 10.1136/jitc-2020-002259
Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors
Pauline Rettman, Matthew D Blunt, Rebecca J Fulton, Andres F Vallejo, Leidy Y Bastidas-Legarda, Laura España-Serrano, Marta E Polak, Aymen Al-Shamkhani, Christelle Retiere, Salim I Khakoo

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e001912; DOI: 10.1136/jitc-2020-001912
Immune profiling of COVID-19: preliminary findings and implications for the pandemic
Holden T Maecker

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e002550; DOI: 10.1136/jitc-2021-002550

Main menu

innate

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

innate

Pages